Brief: Lee's Pharmaceutical Obtained Approval From CDE Of China's NMPA For Socazolimab
27/09/2021 16:20
Sept 27 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* OBTAINED APPROVAL FROM CENTER FOR DRUG EVALUATION OF
CHINA'S
NMPA TO SUBMIT NEW DRUG APPLICATION FOR SOCAZOLIMAB
Source text for Eikon: ID:nHKS7fPCZk
Further company coverage: 0950.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals